Study name: A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of MK-1484 as a Monotherapy and in Combination with Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors (MK-1484-001)
Histology
NSCLC
Tumor stage
Stage IV
Host / recruiting sites
Antoni van Leeuwenhoek
Enrollment
Recruiting
Therapy line
Later line (≥2L)
Design
Fase 1 studie naar veiligheid en verdraagzaamheid van MK-1484 monotherapie of in combinatie met pembrolizumab. Dosisescalatiestudie.
Intervention
MK-1484. IL-2 agonist die bindt aan IL-2, verhoogt T- en NK cell activatie.
Monotherapie of in combinatie met pembrolizumab.
Key outcome parameters
Evaluatie van veiligheid en verdraagzaamheid van MK-1484 en vaststellen van aanbevolen fase 2 dosering.
